StockNews.com started coverage on shares of VBI Vaccines (NASDAQ:VBIV – Get Free Report) in a report issued on Tuesday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock.
VBI Vaccines Price Performance
The firm has a 50 day simple moving average of $0.24 and a 200-day simple moving average of $0.49. VBI Vaccines has a 12-month low of $0.06 and a 12-month high of $1.35.
About VBI Vaccines
See Also
- Five stocks we like better than VBI Vaccines
- The 3 Best Retail Stocks to Shop for in August
- How Much Can You Make in Stocks in One Month?
- Most active stocks: Dollar volume vs share volume
- This Is the Top Large-Cap Stock Insiders Are Buying
- REIT Stocks – Best REIT Stocks to Add to Your Portfolio Today
- Capitalize on Micron’s 24% Drop—Wall Street Eyes Major Upside
Receive News & Ratings for VBI Vaccines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VBI Vaccines and related companies with MarketBeat.com's FREE daily email newsletter.